- Home
- OPT vs PAXS Comparison
OPT vs PAXS Comparison
Compare OPT & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PAXS
- Stock Information
- Founded
- OPT 1984
- PAXS 2021
- Country
- OPT Australia
- PAXS United States
- Employees
- OPT N/A
- PAXS N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PAXS Investment Managers
- Sector
- OPT Health Care
- PAXS Finance
- Exchange
- OPT Nasdaq
- PAXS Nasdaq
- Market Cap
- OPT 855.6M
- PAXS 722.0M
- IPO Year
- OPT 2020
- PAXS N/A
- Fundamental
- Price
- OPT $5.09
- PAXS $16.22
- Analyst Decision
- OPT Strong Buy
- PAXS
- Analyst Count
- OPT 1
- PAXS 0
- Target Price
- OPT $12.00
- PAXS N/A
- AVG Volume (30 Days)
- OPT 40.1K
- PAXS 195.0K
- Earning Date
- OPT 03-03-2025
- PAXS 01-01-0001
- Dividend Yield
- OPT N/A
- PAXS 11.72%
- EPS Growth
- OPT N/A
- PAXS N/A
- EPS
- OPT N/A
- PAXS N/A
- Revenue
- OPT $261,859.00
- PAXS N/A
- Revenue This Year
- OPT N/A
- PAXS N/A
- Revenue Next Year
- OPT $46,864.26
- PAXS N/A
- P/E Ratio
- OPT N/A
- PAXS N/A
- Revenue Growth
- OPT N/A
- PAXS N/A
- 52 Week Low
- OPT $1.79
- PAXS $12.57
- 52 Week High
- OPT $6.30
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- OPT 53.99
- PAXS 59.41
- Support Level
- OPT $4.77
- PAXS $16.03
- Resistance Level
- OPT $5.46
- PAXS $16.26
- Average True Range (ATR)
- OPT 0.32
- PAXS 0.12
- MACD
- OPT -0.11
- PAXS -0.01
- Stochastic Oscillator
- OPT 20.60
- PAXS 56.41
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.